HBOT for Poor Circulation: Can Hyperbaric Oxygen Therapy Improve Blood Flow?

Cold hands and feet that never quite warm up. A cut on the shin that takes weeks instead of days to close. Legs that ache and feel heavy after a short walk. People who notice these patterns often land on the same label: poor circulation. And because hyperbaric oxygen therapy (HBOT) works by flooding the body with pressurized oxygen, it is a natural question to ask whether HBOT for poor circulation is worth considering. The honest answer is more nuanced than a simple yes. HBOT does have real, measurable effects on oxygen delivery and blood vessel growth, but general "poor circulation" as a lay complaint is not an FDA-approved use of the therapy, and the strongest clinical evidence sits in specific diagnosed conditions rather than everyday wellness. This article walks through what is actually known: how HBOT affects blood flow at a mechanical level, where the clinical evidence is strong versus preliminary, and what that distinction means if you are considering it.

Is HBOT FDA-Approved for Poor Circulation?

No. The U.S. Food and Drug Administration has cleared HBOT for a narrow, specific list of indications - among them decompression sickness, air or gas embolism, carbon monoxide poisoning, certain problem wounds including select diabetic foot ulcers, delayed radiation injury, and a handful of other acute or severe conditions. General "poor circulation" in an otherwise healthy or mildly symptomatic adult does not appear anywhere on that list.

That does not make the underlying physiology irrelevant - it means any claims about HBOT and circulation need to be scoped to what has actually been studied, rather than extended into a blanket treatment claim. The sections below separate the mechanism (well-documented), from the evidence in diagnosed conditions (stronger, but specific), from general wellness extrapolation (unsupported).

Hyperbaric Oxygen Therapy and Blood Flow: What Happens in the Body

A single HBOT session produces a two-phase response. In a study measuring 20 healthy volunteers during treatment, peripheral blood flow actually dropped by roughly 7–23% in the first minutes of oxygen exposure, a mild, transient vasoconstriction, before reversing course: tissue oxygen levels rose sharply, by as much as 840–1,513% during the session, and blood flow was measured 4–76% above baseline shortly after the chamber session ended (Yamamoto et al., Diving and Hyperbaric Medicine, 2021). In other words, blood vessels briefly narrow as the body adjusts to the extra oxygen, then circulation rebounds once the session is complete.

A separate small pilot study comparing mild HBOT to regular oxygen at normal pressure found increased capillary blood velocity and flow rate in the fine capillaries of the fingertips in healthy subjects (Nisa et al., J Sports Med Phys Fitness, 2022). The sample was small and the study was explicitly a pilot, so this finding is best read as an early, limited signal rather than proof of a lasting circulation benefit.

Angiogenesis - How HBOT May Encourage New Blood Vessel Growth

Beyond these short-term effects, HBOT is understood to influence angiogenesis, the growth of new blood vessels, over repeated sessions. The proposed pathway runs through oxygen-dependent stabilization of a protein called HIF-1α, which in turn increases secretion of vascular endothelial growth factor (VEGF) and other growth factors, partly through nitric oxide signaling at the cellular level (Thom, Plast Reconstr Surg, 2011; Yamamoto et al., Sci Rep, 2020; Lindenmann et al., Int J Mol Sci, 2021. In an animal model of limb ischemia, HBOT significantly improved new blood vessel formation and reduced markers of oxidative stress compared to untreated controls Lin YC et al., J Cell Mol Med, 2024. This is a meaningful mechanistic signal, but it comes from a mouse model, not a human trial, and should be read as explaining a plausible biological pathway rather than confirming a human circulation benefit.

Can Hyperbaric Oxygen Therapy Help Poor Circulation? What the Research Shows

Pulling these threads together requires being honest about where the evidence is strongest and where it thins out.

The Strongest Evidence - Peripheral Arterial Occlusive Disease (PAOD)

The most direct clinical link between HBOT and improved blood flow comes from a study of 57 patients with diagnosed peripheral arterial occlusive disease, a specific, physician-diagnosed vascular condition. HBOT was associated with increased circulating endothelial progenitor cells, higher levels of angiogenesis biomarkers, and improved measured blood flow in the ischemic limb areas of these patients Lin PY et al., J Clin Med, 2018. This is genuinely encouraging data, but it describes a diagnosed disease population under medical supervision, not a general "my hands are always cold" complaint in an otherwise healthy adult.

The Real Cleared Indication - Problem Wound Healing

The one circulation-adjacent context where HBOT has an actual FDA-cleared indication is problem wound healing, including select diabetic foot ulcers, and even here the evidence is mixed rather than uniformly positive. A Cochrane systematic review found that HBOT improved the rate of diabetic foot ulcer healing at six weeks, but this benefit was not clearly sustained at roughly twelve months, and the review's authors flagged design and reporting limitations across the included trials Kranke et al., Cochrane Database Syst Rev, 2015. A larger meta-analysis of 14 controlled trials involving 768 participants found that HBOT significantly improved complete wound healing and reduced major amputation rates compared to standard care alone, but found no significant benefit for minor amputations, ulcer size reduction, or mortality, and recorded more adverse events in the HBOT group Sharma et al., Sci Rep, 2021. Even in its one genuinely cleared, circulation-adjacent use, HBOT's evidence base is directionally positive but not conclusive on every outcome that matters.

What This Means If You're Dealing With Poor Circulation

Put together, the picture is this: HBOT's effect on oxygen delivery and its role in stimulating new blood vessel growth are real and reasonably well-documented at the physiological level. The clinical proof of a meaningful circulation benefit, however, is strongest in specific, diagnosed conditions managed by a physician - peripheral arterial disease and certain problem wounds - not in general "poor circulation" as a standalone wellness complaint. Using HBOT for that broader purpose remains investigational rather than an established, evidence-backed treatment, and it is worth discussing with a physician rather than assuming it as a fix.

Humanaut Health also offers EBO2 therapy, an extracorporeal blood oxygenation and ozonation treatment whose described benefits include supporting circulation and reducing inflammation through a different mechanism, which may be a relevant conversation for some patients exploring this area. Humanaut Health's broader overview of HBOT benefits, risks, and what a session actually involves covers the general safety and experience picture in more depth for readers who want the fuller context.

Safety Considerations

HBOT is generally described as well-tolerated in clinical settings, but it is not without risk. Reported adverse effects include ear and sinus barotrauma, transient vision changes, and, more rarely, oxygen toxicity; the diabetic-ulcer meta-analysis discussed above also recorded more adverse events in the HBOT group than in standard-care controls Sharma et al., Sci Rep, 2021. HBOT is not a substitute for a physician's diagnosis or treatment of an underlying vascular condition, and anyone considering it for circulation-related symptoms should have those symptoms properly evaluated first.

Frequently Asked Questions

Can HBOT help with poor circulation?

The evidence is mixed and condition-specific. HBOT has documented effects on oxygen delivery and may support new blood vessel growth over time, and clinical evidence in diagnosed conditions like peripheral arterial disease is encouraging. For general "poor circulation" without a specific diagnosis, however, the evidence is preliminary, and HBOT is not an established treatment for that complaint.

Is hyperbaric oxygen therapy FDA-approved for poor circulation?

No. The FDA has cleared HBOT for a specific, narrow list of indications that does not include general poor circulation. The closest cleared, circulation-adjacent use is treatment of certain problem wounds, including select diabetic foot ulcers, under specific clinical criteria.

What does hyperbaric oxygen therapy do to blood flow?

During a session, peripheral blood flow briefly decreases as blood vessels constrict, then tissue oxygen levels rise sharply and blood flow has been measured above baseline shortly after the session ends. Over repeated sessions, HBOT is also thought to encourage new blood vessel growth through oxygen-sensitive signaling pathways.

Is there research on hyperbaric oxygen therapy for poor circulation specifically?

Most of the relevant research examines diagnosed vascular conditions, such as peripheral arterial occlusive disease, or short-term physiology in healthy volunteers, rather than general "poor circulation" as a standalone complaint. A small pilot study did find improved capillary blood flow in healthy subjects after mild HBOT, but it was limited in size and scope.

Does HBOT help with cold hands and feet?

There is no direct clinical trial testing HBOT specifically for cold hands and feet as a standalone symptom. The physiological mechanisms that improve oxygenation and may support blood vessel growth are documented, but extending that to a specific fix for cold extremities is not something the current evidence supports.

Is HBOT proven to treat diabetic foot ulcers?

The evidence is positive but not unqualified. A Cochrane review found improved healing rates at six weeks that were not clearly sustained at a year, and a larger meta-analysis found improved complete healing and fewer major amputations, but no clear benefit on some other outcomes and more recorded adverse events in the treated group.

What are the risks of trying HBOT for circulation?

Reported risks include ear and sinus barotrauma, temporary vision changes, and rare oxygen toxicity. Because general poor circulation is not an FDA-cleared use, anyone considering HBOT for this reason should first have the underlying cause of their symptoms properly evaluated by a physician.

Key Takeaways

• HBOT for poor circulation is not an FDA-approved use; the FDA's cleared indications cover specific conditions such as decompression sickness, select problem wounds, and a handful of other acute conditions.
• A single HBOT session triggers transient vasoconstriction followed by a rise in tissue oxygen and above-baseline blood flow - a real, measured physiological pattern, not a cure.
• HBOT is understood to support new blood vessel growth (angiogenesis) through oxygen-sensitive signaling pathways, a mechanism backed mostly by animal and mechanistic research.
• The strongest clinical evidence for HBOT improving blood flow exists in diagnosed conditions like peripheral arterial occlusive disease and problem wound healing - not in general wellness use.
• Even in its cleared, circulation-adjacent use (diabetic foot ulcers), the evidence is directionally positive but mixed on several outcomes.

Next Steps

If circulation symptoms are a concern, the most useful first step is a physician evaluation to identify the underlying cause, rather than assuming HBOT as a fix. Readers who want to understand how Humanaut Health's HBOT program. is delivered in a clinical setting can learn more about the therapy, its process, and what a session involves.